Monoarthritis revealing Infliximab-induced systemic lupus erythematosus in Crohn’s disease

Case Report

Abstract

Introduction: Infliximab is increasingly used for the treatment of severe and resistant forms of Crohn’s disease (CD). It is characterized by its efficiency and good tolerance. Induced systemic lupus erythematosus (SLE) remains an exceptional but potentially serious complication of this treatment and its diagnosis represents a real challenge for clinicians.

We are reporting an original observation of infliximab-induced SLE in CD whose revealing clinical presentation was an isolated monoarthritis.

Case report: A 28-year-old woman, followed for severe and resistant to first-line treatment CD since the age of 20. Treatment with infliximab was thus initiated with a satisfactory effect. During her admission for the fifth infusion of infliximab, she reported inflammatory arthralgia in the small joints of her hands. Somatic examination noted an isolated arthritis of the proximal interphalangeal joint of the right fifth finger. Biology noted leukopenia at 2000/mm³, neutropenia at 1250/mm³, lymphopenia at 634/mm³, and erythrocyte sedimentation rate at 68mm/H1. Anti-nuclear antibodies were positive at 1/160 and anti-double stranded DNA antibodies were positive at 1/160. Thus, the diagnosis of infliximab-induced SLE was retained. Infliximab was discontinued, and the outcome was favorable under systemic corticosteroid therapy associated with Hydroxychloroquine and Mesalazine.

Conclusion: As rare as it is, this complication of biotherapy deserves to be known by clinicians and the diagnosis deserves to be mentioned in front of any monoarthritis occurring in CD patient under anti-TNFα therapy.

Keywords: monoarthritis, infliximab, systemic lupus erythematosus, Crohn disease, drug-induced lupus

Abbreviations: CD, Crohn’s disease; SLE, systemic lupus erythematosus; UC, ulcerative colitis; ANA, anti-nuclear antibodies; anti-DNA, DNA antibodies

Introduction

Infliximab, a chimeric monoclonal antibody, is an anti-tumor necrosis factor alpha (anti-TNFα) that is increasingly used for the treatment of severe and resistant forms of inflammatory bowel disease (Crohn’s disease (CD) and ulcerative colitis (UC)). It is characterized by its efficiency and good tolerance. Induced systemic lupus erythematosus (SLE) remains an exceptional but potentially serious complication of this biological treatment.

The diagnosis of these cases of infliximab-induced SLE in patient treated for CD represents a real challenge for clinicians for several reasons:

a. Similar clinical signs and symptoms, the possibility of gastrointestinal involvement during lupus, the possibility of lupus-like extra-digestive manifestations during CD, and the overlapping diagnosis criteria for SLE and CD.

b. The possibility of association of these two diseases in the same patient. The frequency of concomitant diagnosis of inflammatory bowel diseases and SLE is estimated at 0.4% and seems to be more frequent for UC than CD.

c. Clinical presentations of induced lupus are often incomplete and nonspecific.

We are reporting an original observation of infliximab-induced SLE in a patient treated for CD, whose revealing clinical presentation was a monoarthritis.

Case report

A 28-year-old Tunisian woman, followed for CD since the age of 20, with severe and resistant to first-line treatment disease. His disease was complicated by colonic involvement with corticosteroid-resistant colitis requiring subtotal colectomy, and fistulising ano-perineal or deformity.

The X-ray of the hands did not show any fracture, joint destruction, no digestive symptoms or extra-digestive manifestations of her CD. Periarticular skin lesions were noted. The patient was afebrile, and had calcium, glucose, ionogram, transaminases, muscle enzymes, lipid

...
parameters, uric acid, creatinine, and serum protein electrophoresis. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies were negative. Anti-nuclear antibodies (ANA) were positive at 1/640 and anti-double stranded DNA antibodies (anti-DNA) were positive at 1/160. Serum complement fractions (C3, C4, C2, and CH50) were without significant abnormalities.

Infliximab-induced SLE has also been reported in other inflammatory bowel diseases such as UC, and with other anti-TNFα therapies such as Adalimumab and Etanercept. The most suggested pathophysiological mechanism for explaining these cases of infliximab-induced SLE is the likely effects of blocking TNFα on anti-DNA auto-antibodies production. Classically, the evolution of induced SLE is rapidly favorable after the withdrawal of infliximab with rapid disappearance of clinical signs and negation of serological and immunohistochemical markers of lupus. Exceptionally prolonged forms of infliximab-induced lupus disease have been reported.

Therapeutic eventualities in these cases are either switching to another anti-TNF alpha or systemic corticosteroid therapy with azathioprine or Mesalazine. Our observation is distinguished by a monosymptomatic clinical presentation of infliximab-induced SLE in CD. To our knowledge, isolated monoarthritis of the interphalangeal joint has not been reported previously as a warning sign of induced lupus in patients with infliximab-treated DC.

### Conclusion

Infliximab-induced SLE remains an exceptional but potentially serious complication in patients with CD. Monosymptomatic and incomplete presentations represent a real diagnostic challenge. As rare as it is, this complication of biotherapy deserves to be known by clinicians and the diagnosis deserves to be mentioned in front of any monoarthritis occurring in CD patient under anti-TNFα therapy.

### Acknowledgments

None.

### Conflicts of interest

The authors declare there is no conflict of interest.